# Shumway Capital

> Shumway Capital is a VC fund in Greenwich backing Biotechnology and Medical. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Greenwich, United States
- Total investments: 11
- Last investment: Sep 2021
- Lead investor: 27%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/shumway-capital
- Website: https://www.shumwaycapital.com

Shumway Capital is an investment firm that uses a unique growth-focused investment model. As entrepreneurs themselves, the investment team has first-hand knowledge of how to help other companies accelerate their growth and realize their specific visions. The firm’s partners invest their own capital and provide a permanent capital base for theirinvestments. They focus on high-growth businesses across a wealth of industries and have a collaborative approach that enables the management team and the company to continue operating their business effectively without any disruption.

## Contacts

5 contacts available for Shumway Capital. Shizune tracks 2 team members at Shumway Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/shumway-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 27% |
| Medical | 2 | 18% |
| Art | 1 | 9% |
| Banking | 1 | 9% |
| FinTech | 1 | 9% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 27% |
| Series D | 3 | 27% |
| Series A | 2 | 18% |
| Series B | 2 | 18% |
| Series E | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chris Shumway | Founder and Managing Partner | 4 | — |
| Chris Lange | Partner | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Elligo Health Research | Elligo Health Research is a healthcare company that revolutionizes the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health careinformatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere. It brings clinical research to physician practices, accelerating the development of pharmaceutical, biotechnology, and medical device products and therapies.Elligo Health Research was founded in 2016 and is headquartered in Austin, Texas. | $135M | Series E | Sep 24, 2021 |  |
| Vedanta Biosciences | Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $68M | Series D | Jul 21, 2021 |  |
| Finch Therapeutics | Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses inpatients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models.Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts. | $90M | Series D | Sep 17, 2020 |  |
| Finch Therapeutics | Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses inpatients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models.Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts. | $53.5M | Series C | Aug 21, 2019 |  |
| Vedanta Biosciences | Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $18.5M | Series C | May 13, 2019 |  |
| Elligo Health Research | Elligo Health Research is a healthcare company that revolutionizes the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health careinformatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere. It brings clinical research to physician practices, accelerating the development of pharmaceutical, biotechnology, and medical device products and therapies.Elligo Health Research was founded in 2016 and is headquartered in Austin, Texas. | $20M | Series C | May 07, 2019 |  |
| Elligo Health Research | Elligo Health Research is a healthcare company that revolutionizes the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health careinformatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere. It brings clinical research to physician practices, accelerating the development of pharmaceutical, biotechnology, and medical device products and therapies.Elligo Health Research was founded in 2016 and is headquartered in Austin, Texas. | $16M | Series B | Mar 20, 2018 |  |
| Finch Therapeutics | Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses inpatients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models.Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts. | $36M | Series B | Mar 01, 2018 |  |
| Artsy | Artsy is the world’s largest online art marketplace. Browse over 1 million artworks by iconic and emerging artists from 4000+ galleries and top auction houses. | $50M | Series D | Jul 18, 2017 |  |
| Elligo Health Research | Elligo Health Research is a healthcare company that revolutionizes the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health careinformatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere. It brings clinical research to physician practices, accelerating the development of pharmaceutical, biotechnology, and medical device products and therapies.Elligo Health Research was founded in 2016 and is headquartered in Austin, Texas. |  | Series A | Mar 01, 2016 |  |

10 of 11 investments shown.

## Co-investors
- [Avenir](https://shizune.co/investors/profile/avenir-growth-capital) — VC Fund, 4 deals together
- [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners) — VC Fund, 3 deals together
- [Noro-Moseley Partners](https://shizune.co/investors/profile/noro-moseley-partners) — VC Fund, 3 deals together
- [Willett Advisors LLC](https://shizune.co/investors/profile/willett-advisors-llc) — VC Fund, 3 deals together
- [Excelerate Health Ventures](https://shizune.co/investors/profile/excelerate-health-ventures) — VC Fund, 2 deals together
- FS Healthcare — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Shumway Capital invest in?

Shumway Capital invests primarily in Biotechnology, Medical and Art startups, most often at Series C and Series D stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Shumway Capital?

Public channels for Shumway Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Shumway Capital?

The team at Shumway Capital includes Chris Shumway (Founder and Managing Partner) and Chris Lange (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co